Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FC084 camphorsulfonate
- Development stage
- Unknown
- Lead developer
- Zhongshan Innovision
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
FC084 camphorsulfonate is an orally bioavailable small molecule inhibitor of the Axl receptor tyrosine kinase, developed by InnoVision Biopharmaceuticals (Zhongshan InnoVision Pharmaceutical Co., Ltd.). Axl is a member of the TAM (Tyro3, Axl, Mer) receptor family and is frequently overexpressed in various malignancies, where it promotes epithelial-to-mesenchymal transition (EMT), tumor cell survival, metastasis, and resistance to both chemotherapy and targeted therapies. By selectively inhibiting Axl, FC084 aims to disrupt these oncogenic processes and restore sensitivity to treatment in patients with advanced or metastatic solid tumors. The compound has been investigated in Phase 1 clinical trials (e.g., CTR20230518) to evaluate its safety, tolerability, and preliminary efficacy in adult patients who have progressed on standard therapies.
- Other names
- FC084 camsylateFC-084 camsylateFC 084 camsylate
02
Targets
AXL (AXL receptor tyrosine kinase)
Beyond the preview
Go deeper on FC084 camphorsulfonate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FC084 camphorsulfonate.